Oxidative stress and antioxidant capacity in sickle cell anaemia patients receiving different treatments and medications for different periods of time

Annals of Hematology

Volumn 91, Issue 4, 2012, Pages 479-489

  Belini Jr , Edis ^a   Da Silva, Danilo Grünig Humberto ^a   De Souza Torres, Lidiane ^a   De Almeida, Eduardo Alves ^a   Cancado, Rodolfo Delfini ^b   Chiattone, Carlos ^b   Bonini Domingos, Claudia Regina ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b FACULDADE DE CIÊNCIAS MÉDICAS DA SANTA CASA DE SÃO PAULO   (Brazil)

Author keywords

Deferasirox; Folic acid; Hydroxyurea; Oxidative stress; Sickle cell anaemia

Indexed keywords

DEFERASIROX; FERRITIN; FOLIC ACID; HYDROXYUREA; IRON; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRANSFERRIN; ANTIOXIDANT; BENZOIC ACID DERIVATIVE; BIOLOGICAL MARKER; IRON CHELATING AGENT; TRIAZOLE DERIVATIVE;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; BIOASSAY; BLOOD TRANSFUSION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DETERMINATION; DRUG DOSE INCREASE; DRUG TOLERABILITY; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; IRON BLOOD LEVEL; IRON CHELATION; IRON OVERLOAD; LIPID PEROXIDATION; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; SCHOOL CHILD; SICKLE CELL ANEMIA; TRANSFERRIN BLOOD LEVEL; TROLOX EQUIVALENT ANTIOXIDANT CAPACITY ASSAY; ADOLESCENT; DRUG EFFECT; LONGITUDINAL STUDY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY;

ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; ANTIOXIDANTS; BENZOIC ACIDS; BIOLOGICAL MARKERS; BLOOD TRANSFUSION; CHILD; FEMALE; HUMANS; IRON CHELATING AGENTS; LIPID PEROXIDATION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OXIDATIVE STRESS; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TRIAZOLES; YOUNG ADULT;

EID: 84860810206     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-011-1340-y     Document Type: Article

References (65)

1. Weatherall D, Hofman K, Rodgers G, Ruffin J, Hrynkow S (2005) A case for developing north-south partnerships for research in sickle cell disease. Blood 105:921-923
2. Bunn HF (1997) Mechanisms of disease-pathogenesis and treatment of sickle cell disease. N Engl J Med 337:762-769
3. Steinberg MH (1999) Management of sickle cell disease. N Engl J Med 340:1021-1030
4. Vekilov PG (2007) Sickle-cell haemoglobin polymerization: is it the primary pathogenic event of sickle-cell anaemia? Br J Haematol 139:173-184
5. Repka T, Hebbel RP (1991) Hydroxyl radical formation by sickle erythrocyte-membranes-role of pathological iron deposits and cytoplasmic reducing agents. Blood 78:2753-2758
6. Reiter CD, Wang X, Tanus-Santos JE, Hogg N, Cannon RO III, Schechter AN et al (2002) Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 8:1383-1389
7. Kato GJ, Hebbel RP, Steinberg MH, Gladwin MT (2009) Vasculopathy in sickle cell disease: biology, pathophysiology, genetics, translational medicine, and new research directions. Am J Hematol 84:618-625
8. Wood KC, Hebbel RP, Granger DN (2005) Endothelial cell NADPH oxidase mediates the cerebral microvascular dysfunction in sickle cell transgenic mice. FASEB J 19:989-991
9. Belcher JD, Mahaseth H, Welch TE, Vilback AE, Sonbol KM, Kalambur VS et al (2005) Critical role of endothelial cell activation in hypoxia-induced vasoocclusion in transgenic sickle mice. Am J Physiol Heart Circ Physiol 288:H2715-H2725
10. Belcher JD, Bryant CJ, Nguyen J, Bowlin PR, Kielbik MC, Bischof JC et al (2003) Transgenic sickle mice have vascular inflammation. Blood 101:3953-3959
11. Frenette PS (2002) Sickle cell vaso-occlusion: multistep and multicellular paradigm. Curr Opin Hematol 9:101-106
12. Conran N, Franco-Penteado CF, Costa FF (2009) Newer aspects of the pathophysiology of sickle cell disease vaso-occlusion. Hemoglobin 33:1-16
13. Rees DC, Williams TN, Gladwin MT (2010) Sickle-cell disease. Lancet 376:2018-2031
14. Covas DT, de Lucena Angulo I, Vianna Bonini PP, Zago MA (2004) Effects of hydroxyurea on the membrane of erythrocytes and platelets in sickle cell anemia. Haematologica 89:273-280
15. Kinney TR, Helms RW, O'Branski EE, Ohene-Frempong K, Wang W, Daeschner C et al (1999) Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood 94:1550-1554
16. Schnog JB, Duits AJ, Muskiet FA, ten Cate H, Rojer RA, Brandjes DP (2004) Sickle cell disease; a general overview. Neth J Med 62:364-374
17. Halsey C, Roberts IAG (2003) The role of hydroxyurea in sickle cell disease. Br J Haematol 120:177-186
18. Hillery CA, Du MC, Wang WC, Scott JP (2000) Hydroxyurea therapy decreases the in vitro adhesion of sickle erythrocytes to thrombospondin and laminin. Br J Haematol 109:322-327
19. Lou TF, Singh M, Mackie A, Li W, Pace BS (2009) Hydroxyurea generates nitric oxide in human erythroid cells: mechanisms for gamma-globin gene activation. Exp Biol Med 234:1374-1382
20. Adams RJ, Mckie VC, Hsu L, Files B, Vichinsky E, Pegelow C et al (1998) Prevention of a first stroke by transfusions in children with sickle, cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 339:5-11
21. Vichinsky E, Butensky E, Fung E, Hudes M, Theil E, Ferrell L et al (2005) Comparison of organ dysfunction in transfused patients with SCD or beta thalassemia. Am J Hematol 80:70-74
22. Cappellini MD, Porter J, El-Beshlawy A, Li CK, Seymour JF, Elalfy M et al (2010) Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion- dependent anemias. Haematologica 95:557-566
23. Steinberg MH (2008) Sickle cell anemia, the first molecular disease: overview of molecular etiology, pathophysiology, and therapeutic approaches. Scientific World Journal 8:1295-1324
24. Bonini-Domingos CR (2006) Metodologias laboratoriais para o diagnóstico de hemoglobinopatias e talassemias. NH, São José do Rio Preto
25. Belini E, Cancado RD, Domingos CRB (2010) The Xmnl polymorphic site 5' to the gene G gamma in a Brazilian patient with sickle cell anaemia-fetal haemoglobin concentration, haematology and clinical features. Arch Med Sci 6:822-825
26. Sutton M, Bouhassira EE, Nagel RL (1989) Polymerase chainreaction amplification applied to the determination of beta-like globin gene-cluster haplotypes. Am J Hematol 32:66-69
27. Ondei LS, Silveira LM, Leite AA, Souza DR, Pinhel MA, Percario S et al (2009) Lipid peroxidation and antioxidant capacity of G6PD-deficient patients with A-(202G>A) mutation. Genet Mol Res 8:1345-1351
28. Uchiyama M, Mihara M (1978) Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal Biochem 86:271-278
29. Miller NJ, Riceevans C, Davies MJ, Gopinathan V, Milner A (1993) A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin Sci 84:407-412
30. Re R, Pellegrini N, Proteggente A, Pannala A, Yang M, Rice- Evans C (1999) Antioxidant activity applying an improved ABTS radical cation decolorization assay. Free Radic Biol Med 26:1231-1237
31. Manfredini V, Lazzaretti LL, Griebeler IH, Santin AP, Brandao VDM, Wagner S et al (2008) Blood antioxidant parameters in sickle cell anemia patients in steady state. J Natl Med Assoc 100:897-902
32. Jain SK, Ross JD, Levy GJ, Duett J (1990) The effect of malonyldialdehyde on viscosity of normal and sickle red blood cells. Biochem Med Metab Biol 44:37-41
33. Sertac A, Bingol F, Aydin S, Uslu A (1997) Peroxidative damage in sickle-cell erythrocyte ghosts: protective effect of allopurinol. Gen Pharmacol 28:427-428
34. Walter PB, Fung EB, Killilea DW, Jiang Q, Hudes M, Madden J et al (2006) Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease. Br J Haematol 135:254-263
35. Wood KC, Granger DN (2007) Sickle cell disease: role of reactive oxygen and nitrogen metabolites. Clin Exp Pharmacol Physiol 34:926-932
36. Aslan M, Ryan TM, Adler B, Townes TM, Parks DA, Thompson JA et al (2001) Oxygen radical inhibition of nitric oxidedependent vascular function in sickle cell disease. Proc Natl Acad Sci USA 98:15215-15220
37. Hebbel RP, Eaton JW, Balasingam M, Steinberg MH (1982) Spontaneous oxygen radical generation by sickle erythrocytes. J Clin Invest 70:1253-1259
38. Landburg PP, Teerlink T, Biemond BJ, Brandjes DP, Muskiet FA, Duits AJ et al (2010) Plasma asymmetric dimethylarginine concentrations in sickle cell disease are related to the hemolytic phenotype. Blood Cells Mol Dis 44:229-232
39. Xia Y, Dawson VL, Dawson TM, Snyder SH, Zweier JL (1996) Nitric oxide synthase generates superoxide and nitric oxide in arginine-depleted cells leading to peroxynitrite-mediated cellular injury. Proc Natl Acad Sci USA 93:6770-6774
40. Morris CR, Kato GJ, Poljakovic M, Wang X, Blackwelder WC, Sachdev V et al (2005) Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA 294:81-90
41. Amer J, Ghoti H, Rachmilewitz E, Koren A, Levin C, Fibach E (2006) Red blood cells, platelets and polymorphonuclear neutrophils of patients with sickle cell disease exhibit oxidative stress that can be ameliorated by antioxidants. Br J Haematol 132:108-113
42. Schacter L, Warth JA, Gordon EM, Prasad A, Klein BL (1988) Altered amount and activity of superoxide dismutase in sickle cell anemia. FASEB J 2:237-243
43. Hebbel RP, Osarogiagbon R, Kaul D (2004) The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation 11:129-151
44. Cighetti G, Duca L, Bortone L, Sala S, Nava I, Fiorelli G et al (2002) Oxidative status and malondialdehyde in beta-thalassaemia patients. Eur J Clin Invest 32:55-60
45. Hebbel RP, Morgan WT, Eaton JW, Hedlund BE (1988) Accelerated autoxidation and heme loss due to instability of sickle hemoglobin. Proc Natl Acad Sci USA 85:237-241
46. Scott MD (2006) H2O2 injury in beta thalassemic erythrocytes: protective role of catalase and the prooxidant effects of GSH. Free Radic Biol Med 40:1264-1272
47. Cao GH, Prior RL (1998) Comparison of different analytical methods for assessing total antioxidant capacity of human serum. Clin Chem 44:1309-1315
48. Erel O (2004) A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem 37:277-285
49. Fasola F, Adedapo K, Anetor J, Kuti M (2007) Total antioxidants status and some hematological values in sickle cell disease patients in steady state. J Natl Med Assoc 99:891-894
50. Shimauti EL, Silva DG, de Almeida EA, Zamaro PJ, Belini Junior E, Bonini-Domingos CR (2010) Serum melatonin level and oxidative stress in sickle cell anemia. Blood Cells Mol Dis 45:297-301
51. Silva DG, Belini Junior E, Torres LS, Ricci Junior O, Lobo CC, Bonini-Domingos CR et al (2011) Relationship between oxidative stress, glutathione S-transferase polymorphisms and hydroxyurea treatment in sickle cell anemia. Blood Cells Mol Dis 47:23-28
52. Poillon WN, Kim BC, Rodgers GP, Noguchi CT, Schechter AN (1993) Sparing effect of hemoglobin-F and hemoglobin-A2 on the polymerization of hemoglobin-S at physiological ligand saturations. Proc Natl Acad Sci U S A 90:5039-5043
53. Dasgupta T, Fabry ME, Kaul DK (2010) Antisickling property of fetal hemoglobin enhances nitric oxide bioavailability and ameliorates organ oxidative stress in transgenic-knockout sickle mice. Am J Physiol Regul Integr Comp Physiol 298:R394-R402
54. Steinberg MH (2009) Genetic etiologies for phenotypic diversity in sickle cell anemia. Scientific World Journal 9:46-67
55. Agil A, Sadrzadeh SMH (2000) Hydroxy-urea protects erythrocytes against oxidative damage. Redox Rep 5:29-34
56. Glickstein H, Ben El R, Link G, Breuer W, Konijn AM, Hershko C et al (2006) Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. Blood 108:3195-3203
57. Wood JC, Tyszka JM, Carson S, Nelson MD, Coates TD (2004) Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood 103:1934-1936
58. Kaul DK, Liu XD, Choong S, Belcher JD, Vercellotti GM, Hebbel RP (2004) Anti-inflammatory therapy ameliorates leukocyte adhesion and microvascular flow abnormalities in transgenic sickle mice. Am J Physiol Heart Circ Physiol 287: H293-H301
59. Sultana C, Shen YM, Rattan V, Johnson C, Kalra VK (1998) Interaction of sickle erythrocytes with endothelial cells in the presence of endothelial cell conditioned medium induces oxidant stress leading to transendothelial migration of monocytes. Blood 92:3924-3935
60. Vichinsky EP, Ohene-Frempong K (2011) Approaches to transfusion therapy and iron overload in patients with sickle cell disease: results of an international survey. Pediatr Hematol Oncol 28:37-42
61. Olivieri NF (1999) The beta-thalassemias. N Engl J Med 341:99-109
62. Porter JB (2001) Practical management of iron overload. Br J Haematol 115:239-252
63. Droge W (2002) Free radicals in the physiological control of cell function. Physiol Rev 82:47-95
64. Kolb AM, Smit NPM, Lentz-Ljuboje R, Osanto S, van Pelt J (2009) Non-transferrin bound iron measurement is influenced by chelator concentration. Anal Biochem 385:13-19
65. Koren A, Fink D, Admoni O, Tennenbaum-Rakover Y, Levin C (2010) Non-transferrin bound labile plasma iron and iron overload in sickle cell disease: a comparative study between sickle cell disease and beta thalassemic patients. Eur J Haematol 84:72-78